Home›Research›Compare›Cagrilintide vs Sermorelin
Peptide ComparisonCagrilintide vs Sermorelin
Cagrilintide
AM833
Half-life: ~7 days
47 providers listed
Sermorelin
GHRH 1-29
Half-life: 10–20 minutes
473 providers listed
Cagrilintide and Sermorelin target different goals — Cagrilintide for Metabolic, Sermorelin for pulsatile GH release via direct GHRH receptor agonism at the pituitary. They're compared here for reference, not as direct substitutes.
Cagrilintide
Half-life
~7 days
Sermorelin
Half-life
10–20 minutes
Cagrilintide and Sermorelin target different goals — Cagrilintide for Metabolic, Sermorelin for GH / IGF Axis. They're compared here for reference; there isn't a single “better” choice between them.
Cagrilintide
Sermorelin
Cagrilintide
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A N…
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with o…
Combination of cagrilintide and semaglutide 2·4 mg for weight management in adults with overweight and obesit…
Cagrilintide 2·4 mg once-weekly subcutaneous injection in adults with overweight or obesity (SCALE-CAGRI): a…
+5 more
Sermorelin
The GH response to low-dose bolus growth hormone-releasing hormone (GHRH(1-29)NH2) is attenuated in patients…
The relative roles of continuous growth hormone-releasing hormone (GHRH(1-29)NH2) and intermittent somatostat…
A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodyb…
About Cagrilintide
Long-acting amylin analogue; acts on amylin/calcitonin receptors to prolong satiety; synergistic with semaglutide in CagriSema combination
About Sermorelin
Sermorelin is a synthetic analogue of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It binds to GHRH receptors on pituitary somatotrophs, stimulating pulsatile GH secretion in a physiological pattern that preserves the natural hypothalamic-pituitary feedback axis — contrasting with direct GH administration. Downstream IGF-1 elevation mediates many of its body composition, tissue-repair, and sleep quality effects.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Cagrilintide
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
Given mechanistic overlap with GLP-1 agonists when used as CagriSema, monitor thyroid C-cell markers (calcitonin), lipase for pancreatitis risk, and a baseline metabolic panel. Amylin-specific monitoring guidance is evolving as Phase 3 data matures; follow prescribing protocol of the co-administered agent.
Sermorelin
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
Sermorelin clinical protocols measure IGF-1 as the primary marker of GH axis response. Fasting glucose and insulin are standard baseline assessments given GH's effect on insulin sensitivity.
Sermorelin
Ipamorelin
Research suggests Sermorelin and Ipamorelin may produce complementary growth hormone release effects when combined. Sermorelin acts as a GHRH analogue via pituitary receptors, while Ipamorelin acts via ghrelin receptors — dual-pathway stimulation studied in GH optimization research.
Cagrilintide
Sermorelin
Where to source these peptides
Cagrilintide
47 listed
Browse directory →
Providers offeringSermorelin
473 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
Related Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated October 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Cagrilintide vs Sermorelin — Per-mg Price Comparison. Retrieved October 27, 2026, from https://peptidebase.io/peptides/compare/cagrilintide/sermorelin